• Home
  •  / Orexigen Therapeutics

Orexigen Therapeutics

OverviewSuggest Edit

Orexigen Therapeutics is a biopharmaceutical company which focuses on the development of pharmaceutical product candidates for the treatment of obesity. The Company's product, Contrave, is approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults. Its solution is a prescription medicine that contains 2 medicines (naltrexone HCl and bupropion HCl) that may help some obese adults, or overweight adults who also have weight-related medical problems, lose weight and keep the weight off.

StateClosed
TypePrivate
Founded2002
HQSan Diego, CA, USMap
Websiteorexigen.com
Employee Ratings3.5More

Recent NewsAll News

Latest Updates

Employees (est.) (Jun 2019)132
Revenue (FY, 2016)$33.7 M(+38%)
Share Price (Jun 2018)$0.2 (-86%)
Cybersecurity ratingBMore

Orexigen Therapeutics Office Locations

Orexigen Therapeutics has an office in San Diego
San Diego, CA, US (HQ)
200 3344 N Torrey Pines Ct
Show all (1)

Orexigen Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2002

Orexigen Therapeutics total Funding

$76 m

Orexigen Therapeutics latest funding size

$30 m

Time since last funding

14 years ago

Orexigen Therapeutics investors

Kleiner Perkins, Scale Venture Partners, Montreux Equity Partners, MPM Capital, Duke University, Domain Associates, Wasatch Advisors
Orexigen Therapeutics's latest funding round in November 2006 was reported to be $30 m. In total, Orexigen Therapeutics has raised $76 m
Show all financial metrics

Orexigen Therapeutics Revenue

Orexigen Therapeutics's revenue was reported to be $33.71 m in FY, 2016 which is a 37.8% increase from the previous period.
USD

Revenue (Q3, 2017)

18.9m

Gross profit (Q3, 2017)

14.9m

Gross profit margin (Q3, 2017), %

78.6%

Net income (Q3, 2017)

(20.8m)

EBIT (Q3, 2017)

(22.8m)

Cash (30-Sept-2017)

45.6m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

4.4m3.4m3.4m55.5m24.5m33.7m

Revenue growth, %

1520%(56%)38%

Cost of goods sold

8.0m

Gross profit

25.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

857.0k857.0k857.0k857.0k857.0k857.0k857.0k857.0k857.0k857.0k30.9m4.4m5.2m10.0m5.0m7.8m7.0m19.1m23.4m18.9m

Cost of goods sold

1.8m1.9m6.2m6.8m4.0m

Gross profit

6.0m5.1m13.0m16.5m14.9m

Gross profit Margin, %

77%72%68%71%79%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

101.7m78.3m98.1m104.2m155.4m92.5m

Accounts Receivable

2.6m6.8m1.1m

Prepaid Expenses

1.1m1.5m1.3m1.5m2.3m

Inventories

1.2m10.8m23.2m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

36.4m33.9m73.4m67.4m56.1m67.1m55.8m48.7m37.6m31.1m68.4m75.1m71.6m154.3m68.0m78.2m74.4m76.7m36.7m45.6m

Accounts Receivable

32.0m4.5m6.8m4.6m2.8m2.9m2.1m6.3m7.6m19.1m

Prepaid Expenses

1.3m897.0k1.3m2.3m1.5m2.0m3.0m1.8m1.3m5.8m1.8m1.3m2.0m2.2m2.6m4.0m6.1m4.9m4.3m6.5m

Inventories

754.0k1.4m4.9m11.1m15.0m11.5m24.0m20.7m15.8m16.1m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(28.1m)(90.1m)(77.7m)(37.5m)(68.7m)(24.5m)

Depreciation and Amortization

443.0k313.0k94.0k139.0k223.0k3.7m

Inventories

(1.2m)(9.6m)1.5m

Accounts Payable

(6.1m)17.3m(2.3m)2.1m1.0m11.8m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(19.2m)(23.8m)(10.4m)(27.1m)(57.6m)(19.4m)(37.6m)(56.2m)(24.9m)(49.4m)(38.1m)(17.2m)(39.7m)(50.9m)(22.3m)(47.6m)85.0k(69.1m)(99.6m)(120.4m)

Depreciation and Amortization

240.0k348.0k83.0k160.0k236.0k76.0k79.0k84.0k8.0k46.0k87.0k51.0k103.0k157.0k78.0k194.0k1.7m2.1m4.2m6.3m

Inventories

(754.0k)(158.0k)(3.7m)(9.8m)(4.1m)(596.0k)618.0k2.4m7.6m7.6m

Accounts Payable

(4.8m)(6.8m)725.0k4.1m13.5m(4.7m)(6.4m)(4.2m)(1.2m)1.7m(1.1m)(3.8m)6.9m4.0m(1.9m)2.5m13.1m3.5m(5.5m)10.5m
show all
USDQ2, 2011

Financial Leverage

3.8 x
Show all financial metrics

Orexigen Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

Learn more about our premium products
SecurityScorecard logo

Orexigen Therapeutics Online and Social Media Presence

Orexigen Therapeutics's Trends

Embed Graph

Orexigen Therapeutics News and Updates

January 07, 2019

Obesity Management Market 2019 Growth, Trends, and Forecast| Roche, GlaxoSmithKline, Orexigen Therapeutics, Arena Pharmaceuticals, Novo Nordisk

Obesity Management Market Report aims to define, describe, and forecast on the basis of Market size, share, types, overview, top key vendors. This research report provides analysis and information according to market segments such as geography, technology and application. Posted via Industry Today. …

 Orexigen Therapeutics Frequently Asked Questions

  • When was Orexigen Therapeutics founded?

    Orexigen Therapeutics was founded in 2002.

  • How many employees does Orexigen Therapeutics have?

    Orexigen Therapeutics has 132 employees.

  • What is Orexigen Therapeutics revenue?

    Latest Orexigen Therapeutics annual revenue is $33.7 m.

  • What is Orexigen Therapeutics revenue per employee?

    Latest Orexigen Therapeutics revenue per employee is $255.4 k.

  • Who are Orexigen Therapeutics competitors?

    Competitors of Orexigen Therapeutics include Otonomy, Ironwood Pharmaceuticals and Biogen.

  • Where is Orexigen Therapeutics headquarters?

    Orexigen Therapeutics headquarters is located at 200 3344 N Torrey Pines Ct, San Diego.

  • Where are Orexigen Therapeutics offices?

    Orexigen Therapeutics has an office in San Diego.

  • How many offices does Orexigen Therapeutics have?

    Orexigen Therapeutics has 1 office.